Regeneron Pharmaceuticals Inc (REGN)

Cash ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cash and cash equivalents	US$ in thousands	2,730,000	2,152,300	1,937,200	3,916,300	3,105,900	3,491,300	3,395,100	3,345,700	2,885,600	3,432,400	2,072,200	1,437,900	2,193,700	1,573,000	1,992,200	2,208,200	1,617,800	1,384,800	1,045,500	1,708,500
Short-term investments	US$ in thousands	8,114,800	7,761,300	6,990,500	5,043,400	4,636,400	3,530,400	4,171,300	3,704,900	2,809,100	2,355,200	1,838,600	2,065,900	1,393,300	1,452,900	1,152,000	1,795,200	1,596,500	1,493,100	1,624,200	1,523,900
Total current liabilities	US$ in thousands	3,423,400	3,598,600	3,104,400	3,100,100	3,141,300	2,879,200	3,033,900	3,007,600	3,932,500	3,714,800	3,732,400	3,217,800	2,697,400	2,337,800	3,702,400	2,055,200	2,096,600	1,765,400	1,713,100	1,511,400
Cash ratio		3.17	2.75	2.88	2.89	2.46	2.44	2.49	2.34	1.45	1.56	1.05	1.09	1.33	1.29	0.85	1.95	1.53	1.63	1.56	2.14

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($2,730,000K + $8,114,800K) ÷ $3,423,400K
= 3.17

The cash ratio for Regeneron Pharmaceuticals, Inc. has demonstrated a positive trend over the past eight quarters, indicating the company's strong ability to cover its short-term liabilities with cash and cash equivalents. The ratio has consistently been above 2, reflecting a healthy liquidity position for the company.

The highest cash ratio was observed in Q4 2023 at 3.28, suggesting a significant increase in the company's ability to settle its short-term obligations using its available cash resources. This indicates that the company has a substantial amount of cash on hand relative to its current liabilities.

Overall, the trend in the cash ratio for Regeneron Pharmaceuticals, Inc. indicates a strong financial position with healthy liquidity levels. It suggests that the company has the ability to meet its short-term financial obligations without the need for additional borrowing or liquidation of long-term assets.